Reported 1 day ago
Eli Lilly and Company (NYSE: LLY) announced Q2 2025 results showing a 38% revenue growth to $15.56 billion, driven by Zepbound and Mounjaro. The company raised its 2025 revenue guidance midpoint by $1.5 billion to a range of $60 billion–$62 billion and reported EPS projections between $20.85 and $22.10. Despite positive advances in R&D, including promising oncology and cardiometabolic health studies, Lilly's stock faced pressure after CVS favored a competitor's drug. R&D expenses rose to $3.34 billion as the company continues to invest in its portfolio.
Source: YAHOO